Transfusion

Cover image for Vol. 55 Issue S2

Special Issue: Hemolysis Supplement Strategies to Address Hemolytic Complications of Immune Globulin Infusions

July 2015

Volume 55, Issue S2

Pages i–ii, S1–S127

  1. DEDICATION

    1. Top of page
    2. DEDICATION
    3. LETTER FROM THE EDITORS
    4. INTRODUCTION
    5. PATHOGENESIS AND EPIDEMIOLOGY OF IG PRODUCT-RELATED HEMOLYSIS
    6. PRODUCT RISK FACTORS
    7. IMMUNE GLOBULIN MANUFACTURING AND RISK MITIGATION
    8. SUMMARY AND FUTURE DIRECTIONS
    1. Publication of this supplement is made possible by support provided by the Food and Drug Administration and the Plasma Protein Therapeutics Association (PPTA).

      Dedication (pages i–ii)

      Donald R. Branch

      Article first published online: 14 JUL 2015 | DOI: 10.1111/trf.13244

  2. LETTER FROM THE EDITORS

    1. Top of page
    2. DEDICATION
    3. LETTER FROM THE EDITORS
    4. INTRODUCTION
    5. PATHOGENESIS AND EPIDEMIOLOGY OF IG PRODUCT-RELATED HEMOLYSIS
    6. PRODUCT RISK FACTORS
    7. IMMUNE GLOBULIN MANUFACTURING AND RISK MITIGATION
    8. SUMMARY AND FUTURE DIRECTIONS
    1. Editors' Notes (page S1)

      Harvey G. Klein and George B. Schreiber

      Article first published online: 14 JUL 2015 | DOI: 10.1111/trf.13249

  3. INTRODUCTION

    1. Top of page
    2. DEDICATION
    3. LETTER FROM THE EDITORS
    4. INTRODUCTION
    5. PATHOGENESIS AND EPIDEMIOLOGY OF IG PRODUCT-RELATED HEMOLYSIS
    6. PRODUCT RISK FACTORS
    7. IMMUNE GLOBULIN MANUFACTURING AND RISK MITIGATION
    8. SUMMARY AND FUTURE DIRECTIONS
  4. PATHOGENESIS AND EPIDEMIOLOGY OF IG PRODUCT-RELATED HEMOLYSIS

    1. Top of page
    2. DEDICATION
    3. LETTER FROM THE EDITORS
    4. INTRODUCTION
    5. PATHOGENESIS AND EPIDEMIOLOGY OF IG PRODUCT-RELATED HEMOLYSIS
    6. PRODUCT RISK FACTORS
    7. IMMUNE GLOBULIN MANUFACTURING AND RISK MITIGATION
    8. SUMMARY AND FUTURE DIRECTIONS
    1. Epidemiology and Risk Factors for IG-related Hemolysis

      The role of isoagglutinins in intravenous immunoglobulin–related hemolysis (pages S13–S22)

      Caroline L. Bellac, Thomas Hottiger, Markus P. Jutzi, Katja Bögli-Stuber, Michael Sänger, Kay-Martin Hanschmann, Brigitte Keller-Stanislawski and Markus B. Funk

      Article first published online: 14 JUL 2015 | DOI: 10.1111/trf.13113

    2. Complementary use of passive surveillance and Mini-Sentinel to better characterize hemolysis after immune globulin (pages S28–S35)

      Scott Winiecki, Bethany Baer, Wambui Chege, Christopher Jankosky, Paul Mintz, Meghan Baker, Tiffany Woodworth and Michael Nguyen

      Article first published online: 14 JUL 2015 | DOI: 10.1111/trf.13116

    3. Pathogenesis of Hemolysis

    4. The role of inflammation in intravenous immune globulin–mediated hemolysis (pages S65–S73)

      Jacob Pendergrast, Kezia Willie-Ramharack, Lorna Sampson, Vincent Laroche and Donald R. Branch

      Article first published online: 14 JUL 2015 | DOI: 10.1111/trf.13097

  5. PRODUCT RISK FACTORS

    1. Top of page
    2. DEDICATION
    3. LETTER FROM THE EDITORS
    4. INTRODUCTION
    5. PATHOGENESIS AND EPIDEMIOLOGY OF IG PRODUCT-RELATED HEMOLYSIS
    6. PRODUCT RISK FACTORS
    7. IMMUNE GLOBULIN MANUFACTURING AND RISK MITIGATION
    8. SUMMARY AND FUTURE DIRECTIONS
    1. Anti-A and Anti-B Haemagglutinins in IG Products

    2. Other Product Risk Factors for Hemolysis

    3. Intravenous immunoglobulin–related hemolysis in patients treated for Kawasaki disease (pages S90–S94)

      Naomi L.C. Luban, Edward C.C. Wong, Rodolfo Henrich Lobo, Philippe Pary and Sarah Duke

      Article first published online: 14 JUL 2015 | DOI: 10.1111/trf.13089

  6. IMMUNE GLOBULIN MANUFACTURING AND RISK MITIGATION

    1. Top of page
    2. DEDICATION
    3. LETTER FROM THE EDITORS
    4. INTRODUCTION
    5. PATHOGENESIS AND EPIDEMIOLOGY OF IG PRODUCT-RELATED HEMOLYSIS
    6. PRODUCT RISK FACTORS
    7. IMMUNE GLOBULIN MANUFACTURING AND RISK MITIGATION
    8. SUMMARY AND FUTURE DIRECTIONS
    1. Donor plasma and anti-A/anti-B levels

      Donor screening reduces the isoagglutinin titer in immunoglobulin products (pages S95–S97)

      Brigitte Siani, Katharina Willimann, Sandra Wymann, Adriano Marques Antunes and Eleonora Widmer

      Article first published online: 14 JUL 2015 | DOI: 10.1111/trf.13095

    2. Anti-A and anti-B titers in donor plasma, plasma pools, and immunoglobulin final products (pages S98–S104)

      John McVey, Don Baker, Rajesh Parti, Roger Berg, Maria Gudino and Wolfgang Teschner

      Article first published online: 15 MAY 2015 | DOI: 10.1111/trf.13114

    3. Immune Globulin manufacturing and clearance of isoagglutinins

    4. Anti-A and anti-B hemagglutinin depletion during Cohn purification process of 5% immunoglobulin (pages S110–S116)

      Alfonso Salvatore, Semih Esin, Giovanna Batoni, Ester Ascione, Claudio Farina and Claudia Nardini

      Article first published online: 14 JUL 2015 | DOI: 10.1111/trf.13112

    5. Isoagglutinin reduction by a dedicated immunoaffinity chromatography step in the manufacturing process of human immunoglobulin products (pages S117–S121)

      Liane Hoefferer, Isabelle Glauser, Annette Gaida, Katharina Willimann, Adriano Marques Antunes, Brigitte Siani, Sandra Wymann, Eleonora Widmer, Ibrahim El Menyawi, Reinhard Bolli, Martin Spycher and Martin Imboden

      Article first published online: 14 JUL 2015 | DOI: 10.1111/trf.13088

  7. SUMMARY AND FUTURE DIRECTIONS

    1. Top of page
    2. DEDICATION
    3. LETTER FROM THE EDITORS
    4. INTRODUCTION
    5. PATHOGENESIS AND EPIDEMIOLOGY OF IG PRODUCT-RELATED HEMOLYSIS
    6. PRODUCT RISK FACTORS
    7. IMMUNE GLOBULIN MANUFACTURING AND RISK MITIGATION
    8. SUMMARY AND FUTURE DIRECTIONS

SEARCH

SEARCH BY CITATION